reports
Iterum Therapeutics Reports First Quarter 2024 Financial Results
Iterum Therapeutics Reports First Quarter 2024 Financial Results --NDA Resubmitted; FDA Action Expected in Early Q4 24-- --Cash Runway into 2025, including through Potential FDA Approval-- --Company to Host Conference Call Today at 8:30 a.m. EDT-- DUBLIN, Ireland and CHICAGO, May 13, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), (Iterum) a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported fi...
Dentsply Sirona to Participate in Upcoming Investor Conferences
Dentsply Sirona to Participate in Upcoming Investor Conferences CHARLOTTE, N.C., May 08, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced its participation at upcoming conferences. Bank of America 2024 Health Care Conference on May 15, 2024, at 9:20 am PT (12:20 pm ET)Stifel 2024 Jaws and Paws Conference on May 29, 2024, at 12:40 pm ET Investors and other interested parties will be able to access a live audio webcast and audio webcast replay by visiting the Investors section of the Dentsply Sirona website at About Dentsp...
Vintage Wine Announces Forbearance Agreement Extension with Lenders
SANTA ROSA, Calif.--(BUSINESS WIRE)-- (Nasdaq: VWE and VWEWW) (the “Company”) today announced that the Company and its lender group have amended the amended and restated forbearance agreement dated April 2, 2024 (as amended, the “amended forbearance agreement”) to extend the forbearance period to June 4, 2024. The lenders have also agreed to defer the $10 million principal payment previously due at May 15, 2024 to June 17, 2024. Under the amendment to the amended and restated forbearance agreement, the lender group has agreed to not exercise any rights and remedies until June 4, 2024, so lo...
Iterum Therapeutics to Report First Quarter 2024 Financial Results on ...
Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024 DUBLIN, Ireland and CHICAGO, May 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its first quarter 2024 financial results before the open of the U.S. financial markets on Monday, May 13, 2024. Management will host a conference ...
- Jonathan Moreland
SPWR SUNPOWER CORPORATION
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
FRAF FRANKLIN FINANCIAL SERVICES CO.
ZM ZOOM VIDEO COMMUNICATIONS
MRBK INC.
RYES MERIDIAN
LUMN PATRIOT MINEFINDERS INC.
VPV LUMEN TECHNOLOGIES INC.
MEGI INVESCO PA VALUE MUNI INC TST
IZEA MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
IZEA WORLDWIDE INC
Dentsply Sirona Reports First Quarter 2024 Results
Dentsply Sirona Reports First Quarter 2024 Results Net sales of $953 million decreased (2.6%), organic sales decreased (1.9%)GAAP gross margin of 53.1%, GAAP net income of $18 million or $0.09 per shareAdjusted EBITDA margin of 16.8%, adjusted EPS of $0.42Maintaining FY24 outlook for organic sales and adjusted EPS, trending towards the low-end of both ranges; reported sales adjusted for additional foreign currency impactCompany expects to repurchase up to $150 million of its common stock in Q2 2024 CHARLOTTE, N.C, May 02, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” o...
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Dr...
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem --First Oral Penem in the U.S. and Second New Oral Treatment for uUTIs in Over 25 Years, if approved-- --Potential Approval Early Q4 2024-- DUBLIN, Ireland and CHICAGO, April 29, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it ...
- Jonathan Moreland
- Jonathan Moreland
- Jonathan Moreland
- Jonathan Moreland
Dentsply Sirona to Host First Quarter Conference Call on May 2nd
Dentsply Sirona to Host First Quarter Conference Call on May 2nd CHARLOTTE, N.C., April 09, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will be hosting an investor conference call and live webcast on Thursday, May 2, 2024, at 8:30 am ET to review its first quarter financial results. A presentation related to the call will be available on the Investors section of the Company’s website at Conference Call / Webcast Information A live webcast will be available on the Investors section of the Company’s we...
- Jonathan Moreland
BRT BRT APARTMENTS
FPF FIRST TRUST INTERMEDIATE DURATION PREFERRED AND INCOME FUND
ZM ZOOM VIDEO COMMUNICATIONS
EGLE INC.
MPA EAGLE BULK SHIPPING
BUKS BLACKROCK MUNIYIELD PENNSYLVANIA FD
NPCT BUTLER NATIONAL CORP
ASGI NUVEEN CORE PLUS IMPACT FD
ABERDEEN STANDARD GLOBAL INFRASTRUCTURE INCOME FUND
- Jonathan Moreland
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
BRT BRT APARTMENTS
FMN FEDERATED PREMIER MUNICIPAL INCOME FUND
ZM ZOOM VIDEO COMMUNICATIONS
BFZ INC.
MPA BLACKROCK CALIF MUN INCOME TRUST
AMPX BLACKROCK MUNIYIELD PENNSYLVANIA FD
BIGZ AMPRIUS TECHNOLOGIES INC
ECAT BLACKROCK INNOVATION AND GROWTH TST
NPCT BLACKROCK ESG CAP ALLOCATION TR
ELVN NUVEEN CORE PLUS IMPACT FD
BMEZ IMARA INC
ASGI BLACKROCK HEALTH SCIENCES TERM TRUST
ABERDEEN STANDARD GLOBAL INFRASTRUCTURE INCOME FUND
CORRECTING and REPLACING Vintage Wine Announces Forbearance Agreement ...
SANTA ROSA, Calif.--(BUSINESS WIRE)-- First paragraph, first sentence of release should read: ...the Company and its lender group have amended the forbearance agreement dated February 28, 2024... (instead of ...the Company and its lender group have amended the forbearance agreement dated March x, 2024...) The updated release reads: VINTAGE WINE ANNOUNCES FORBEARANCE AGREEMENT EXTENSION WITH LENDERS (Nasdaq: VWE and VWEWW) (“VWE” or the “Company”) today announced that the Company and its lender group have amended the forbearance agreement dated February 28, 2024 to extend the forbearanc...
Vintage Wine Estates Announces Appointment of Steven Strom to Board of...
SANTA ROSA, Calif.--(BUSINESS WIRE)-- (Nasdaq: VWE and VWEWW) (“VWE” or the “Company”) today announced the appointment of Steven Strom to its Board of Directors, as of March 28, 2024. As an independent director, Mr. Strom will serve as the Chair of the Finance Committee, which also includes Robert L. Berner III, Mark Harms, Jon Moramarco and Patrick Roney. This press release features multimedia. View the full release here: (Photo: Business Wire) “We are excited to add Steven’s significant experience in completing challenging financings and financial restructurings to our Board. We believe hi...
Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financia...
Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results --Resubmission of NDA On Track for Early Q2 24— --Cash Runway into 2025, including through Potential FDA Approval in Early Q4 24-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, March 28, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported fina...
- Jonathan Moreland
Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financ...
Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024 DUBLIN, Ireland and CHICAGO, March 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its fourth quarter and full year 2023 financial results before the open of the U.S. financial markets on Thursday, March 28, 20...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.